NCT06480526Active, not recruiting
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
LEGACY (Late Effects of GD2 Antibody and Chemotherapy in Youths): Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL). Primary Objective To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) study infrastructure, in survivors of HR-NBL (high-risk neuroblastoma) who are greater than 2 years from completion of contemporary therapy and were previously treated at SJCRH (St. Jude Children's Research Hospital). Exploratory Objectives * To describe the health outcomes of survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy. * To describe the relationship between patient outcomes and social determinants of health (SDOH) in survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 34 (actual)
- First submitted
- 14 Jun 2024
- Start date
- 21 Oct 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- St. Jude Children's Research Hospital
- Diseases
- Neuroblastoma
- NCT number
- NCT06480526
What you commit to
- Study type: Observational
- Participants enrolled: 34
- From 21 Oct 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants who had relapsed or refractory disease during or following completion of modern era treatment for HR-NBL.
Other
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
- Participants who are pregnant or breastfeeding.
- Participants who are unable to read and understand English
Who the study is looking for
- Participants were diagnosed with neuroblastoma at \< 18 years of age and categorized as high-risk at that time, according to INSS26 or INRGSS27 criteria.
- Participants were treated for HR-NBL at SJCRH on NB2012 or as per NB2012.
- Participants are ≥ 2 years from completion of therapy. Participants are 5 years of age or older.
- Participant or legal guardian is able and willing to give informed consent.
- Participants may choose to participate in all or a fraction of the proposed assessments; refusal to participate in some aspects of the study will not preclude their inclusion.
- Participants must also complete enrollment on SJLIFE.
Age in the registry: 5 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Jude Children's Research Hospital Coordinator of this site? Confirm its status | Memphis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.